文献速递乳房整形与再造美容整形

一期乳房增大联合悬吊术:2183例连续手术的十年回顾性研究

One-Stage Augmentation Mastopexy: A Retrospective Ten-Year Review of 2183 Consecutive Procedures.
PubMed 文献 · Aesthet Surg J · 2019-01-01

该研究回顾2006年1月至2016年8月1131例患者共2183例连续一期乳房增大联合悬吊术,平均随访43个月(范围4-121个月),总体并发症率15.3%、再手术率14.7%,提示该术式可安全实施且再手术率显著低于分期手术。

要点

  • 总体并发症率15.3%、再手术率14.7%,平均随访43个月。
  • 乳晕周围切口技术再手术率25.7%(P<0.0005),吸烟者并发症26.1%、再手术22.5%(P<0.0005)。
  • 最常见再手术指征为复发下垂3.5%与要求更换假体尺寸3.2%。

核心结论

  • 一期乳房增大联合悬吊术可安全实施,其再手术率显著低于分期手术。
  • 该术式有效性体现在低并发症率与减少患者手术次数。

研究设计与样本

  • 回顾性研究,纳入2006年1月至2016年8月1131例患者的2183例连续一期乳房增大联合悬吊术。
  • 分析患者人口学、手术技术与假体规格,并记录长期并发症与再手术率。

主要发现

  • 平均随访43个月(范围4-121个月),总体并发症率15.3%(n=173),再手术率14.7%(n=166)。
  • 组织相关并发症:增生性瘢痕2.5%(n=28)、复发下垂2.1%(n=24)。
  • 假体相关最常见并发症为包膜挛缩(Baker III或IV)2.8%(n=32)。
  • 再手术最常见指征为复发下垂3.5%(n=40例)与希望更换假体尺寸3.2%(n=36例)。
  • 乳晕周围切口技术再手术率25.7%(P<0.0005);吸烟史者并发症26.1%、再手术22.5%(P<0.0005)。

临床怎么用

  • 术前应评估吸烟史并告知其并发症与再手术风险升高。
  • 选择乳晕周围切口技术时需权衡其更高的再手术率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although numerous studies supporting breast augmentation with simultaneous mastopexy have been reported, concerns persist among surgeons regarding the safety of this procedure. OBJECTIVES: The authors sought to evaluate the safety and effectiveness of 1-stage augmentation mastopexy by analyzing long-term complication and reoperation rates. METHODS: The authors conducted a retrospective review of 1131 patients who underwent 2183 consecutive 1-stage augmentation mastopexy procedures from January 2006 to August 2016. Patient demographics, operative technique, and implant specifications were measured and analyzed with surgical outcomes. Long-term complication and reoperation rates were noted. RESULTS: Over a mean follow-up period of 43 months (range, 4-121 months), the overall complication rate was 15.3% (n = 173) with a reoperation rate of 14.7% (n = 166). Tissue-related complications included hypertrophic scarring in 2.5% (n = 28) and recurrent ptosis in 2.1% (n = 24). The most common implant-related complication was capsular contracture (Baker III or IV) in 2.8% (n = 32). The most common indications for reoperation were recurrent ptosis in 3.5% (n = 40 patients) and desire to change implant size in 3.2% (n = 36 patients). Circumareolar augmentation mastopexy technique was associated with a higher reoperation rate of 25.7% (P < 0.0005). Patients with a history of smoking had a higher incidence of complications (26.1%) and reoperations (22.5%; P < 0.0005). There were no cases of significant skin flap necrosis (>2 cm). CONCLUSIONS: One-stage augmentation mastopexy can be safely performed with a reoperation rate that is significantly lower than when the procedure is staged. The effectiveness of this procedure is defined by a low complication rate and a reduced number of operations for the patient.

来源:Aesthet Surg J,查看原文。版权归原作者所有。

引用

  1. Messa CA, Messa CA. One-Stage Augmentation Mastopexy: A Retrospective Ten-Year Review of 2183 Consecutive Procedures. Aesthet Surg J. 2019. PMID: 31077272. doi:10.1093/asj/sjz143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。